Ipsen announces its decision to extend its collaboration and licensing agreement with Exelixis, for the development of its Cabometyx in advanced pancreatic neuroendocrine tumors (TNEp) and advanced extra-pancreatic tumors (TNEep).

The agreement is based on the results of the CABINET Phase III trial, conducted by the Alliance for Clinical Trials in Oncology, which demonstrated an improvement in progression-free survival for Cabometyx compared with placebo.

This decision enables Ipsen to seek potential marketing approvals for Cabometyx in the treatment of TNEp and TNEep outside the United States and Japan. The laboratory will submit a regulatory dossier in the European Union.

Copyright (c) 2024 CercleFinance.com. All rights reserved.